早期评估心脏手术区域内的新型警报,以促进基因型指导下的抗血小板治疗

IF 1.3 Q4 PHARMACOLOGY & PHARMACY Journal of the American College of Clinical Pharmacy : JACCP Pub Date : 2024-05-03 DOI:10.1002/jac5.1956
Joel Van Heukelom Pharm.D., MBA, Max Weaver M.S., Carson Max B.S., Jordan F. Baye Pharm.D., M.A., Ashley Peterson AAS, Andrii Maryniak M.D., Tomsaz P. Stys M.D., Amanda Massmann Pharm.D.
{"title":"早期评估心脏手术区域内的新型警报,以促进基因型指导下的抗血小板治疗","authors":"Joel Van Heukelom Pharm.D., MBA,&nbsp;Max Weaver M.S.,&nbsp;Carson Max B.S.,&nbsp;Jordan F. Baye Pharm.D., M.A.,&nbsp;Ashley Peterson AAS,&nbsp;Andrii Maryniak M.D.,&nbsp;Tomsaz P. Stys M.D.,&nbsp;Amanda Massmann Pharm.D.","doi":"10.1002/jac5.1956","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Clopidogrel remains widely utilized in patients undergoing percutaneous coronary intervention despite compelling evidence that genetic variation impacts patient response to clopidogrel. Clinical decision support (CDS) is frequently used to aid in precision medicine; however, limitations within the electronic medical record can hinder reliable CDS. Procedural areas where standard order entry is not utilized create a barrier to CDS implementation.</p>\n </section>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>We aimed to evaluate the implementation of a novel alerting mechanism on genotype-guided antiplatelet prescribing within the cardiac catheterization laboratory procedural setting.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A retrospective cohort study was conducted to assess the rate of antiplatelet ordering in patients with one or two loss-of-function cytochrome P450 2C19 (<i>CYP2C19</i>) alleles before and after alert implementation. Pharmacogenomic congruence was measured before and after the alert via chart abstraction that included the <i>CYP2C19</i> genotype and antiplatelet medications ordered within that encounter.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 236 patients were included in analyses, 127 encounters within the cohort before alert implementation and 136 encounters in the cohort after alert implementation. Prior to alert implementation, 40.9% (<i>n</i> = 127) were prescribed clopidogrel compared with 25.7% (<i>n</i> = 136) post implementation. After implementing a genotype-guided alert within the cardiac catheterization laboratory procedural setting, providers were 2.22 times more likely to prescribe an alternative antiplatelet (<i>p</i> = 0.024). Clopidogrel-naïve patients were 9.75 times more likely to receive a genotype-guided antiplatelet order following alert implementation (<i>p</i> &lt; 0.05).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Providers were responsive to a novel alert within the cardiac catheterization laboratory procedural setting. Genotype-guided antiplatelet prescribing significantly increased following the alert implementation.</p>\n </section>\n </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Early evaluation of a novel alert within cardiac procedural areas to facilitate genotype-guided antiplatelet therapy\",\"authors\":\"Joel Van Heukelom Pharm.D., MBA,&nbsp;Max Weaver M.S.,&nbsp;Carson Max B.S.,&nbsp;Jordan F. Baye Pharm.D., M.A.,&nbsp;Ashley Peterson AAS,&nbsp;Andrii Maryniak M.D.,&nbsp;Tomsaz P. Stys M.D.,&nbsp;Amanda Massmann Pharm.D.\",\"doi\":\"10.1002/jac5.1956\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>Clopidogrel remains widely utilized in patients undergoing percutaneous coronary intervention despite compelling evidence that genetic variation impacts patient response to clopidogrel. Clinical decision support (CDS) is frequently used to aid in precision medicine; however, limitations within the electronic medical record can hinder reliable CDS. Procedural areas where standard order entry is not utilized create a barrier to CDS implementation.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Objectives</h3>\\n \\n <p>We aimed to evaluate the implementation of a novel alerting mechanism on genotype-guided antiplatelet prescribing within the cardiac catheterization laboratory procedural setting.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>A retrospective cohort study was conducted to assess the rate of antiplatelet ordering in patients with one or two loss-of-function cytochrome P450 2C19 (<i>CYP2C19</i>) alleles before and after alert implementation. Pharmacogenomic congruence was measured before and after the alert via chart abstraction that included the <i>CYP2C19</i> genotype and antiplatelet medications ordered within that encounter.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>A total of 236 patients were included in analyses, 127 encounters within the cohort before alert implementation and 136 encounters in the cohort after alert implementation. Prior to alert implementation, 40.9% (<i>n</i> = 127) were prescribed clopidogrel compared with 25.7% (<i>n</i> = 136) post implementation. After implementing a genotype-guided alert within the cardiac catheterization laboratory procedural setting, providers were 2.22 times more likely to prescribe an alternative antiplatelet (<i>p</i> = 0.024). Clopidogrel-naïve patients were 9.75 times more likely to receive a genotype-guided antiplatelet order following alert implementation (<i>p</i> &lt; 0.05).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Providers were responsive to a novel alert within the cardiac catheterization laboratory procedural setting. Genotype-guided antiplatelet prescribing significantly increased following the alert implementation.</p>\\n </section>\\n </div>\",\"PeriodicalId\":73966,\"journal\":{\"name\":\"Journal of the American College of Clinical Pharmacy : JACCP\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2024-05-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the American College of Clinical Pharmacy : JACCP\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jac5.1956\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American College of Clinical Pharmacy : JACCP","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jac5.1956","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

尽管有确凿证据表明基因变异会影响患者对氯吡格雷的反应,但氯吡格雷仍被广泛用于接受经皮冠状动脉介入治疗的患者。临床决策支持(CDS)经常被用来帮助精准医疗;然而,电子病历的局限性可能会阻碍可靠的 CDS。我们进行了一项回顾性队列研究,以评估在实施警报前后具有一个或两个功能缺失细胞色素 P450 2C19 (CYP2C19) 等位基因的患者的抗血小板处方率。警报实施前后的药物基因组学一致性是通过病历摘要进行测量的,病历摘要包括CYP2C19基因型和在该次就诊中订购的抗血小板药物。分析共纳入了236名患者,警报实施前队列中有127次就诊,警报实施后队列中有136次就诊。实施预警前,40.9%(n=127)的患者被处方氯吡格雷,而实施预警后,25.7%(n=136)的患者被处方氯吡格雷。在心导管室手术环境中实施基因型指导警报后,医疗服务提供者开具替代抗血小板药物处方的可能性增加了 2.22 倍(p = 0.024)。在实施警报后,氯吡格雷无效患者接受基因型指导的抗血小板药物处方的可能性增加了 9.75 倍(p < 0.05)。实施警报后,基因型指导下的抗血小板处方明显增加。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Early evaluation of a novel alert within cardiac procedural areas to facilitate genotype-guided antiplatelet therapy

Introduction

Clopidogrel remains widely utilized in patients undergoing percutaneous coronary intervention despite compelling evidence that genetic variation impacts patient response to clopidogrel. Clinical decision support (CDS) is frequently used to aid in precision medicine; however, limitations within the electronic medical record can hinder reliable CDS. Procedural areas where standard order entry is not utilized create a barrier to CDS implementation.

Objectives

We aimed to evaluate the implementation of a novel alerting mechanism on genotype-guided antiplatelet prescribing within the cardiac catheterization laboratory procedural setting.

Methods

A retrospective cohort study was conducted to assess the rate of antiplatelet ordering in patients with one or two loss-of-function cytochrome P450 2C19 (CYP2C19) alleles before and after alert implementation. Pharmacogenomic congruence was measured before and after the alert via chart abstraction that included the CYP2C19 genotype and antiplatelet medications ordered within that encounter.

Results

A total of 236 patients were included in analyses, 127 encounters within the cohort before alert implementation and 136 encounters in the cohort after alert implementation. Prior to alert implementation, 40.9% (n = 127) were prescribed clopidogrel compared with 25.7% (n = 136) post implementation. After implementing a genotype-guided alert within the cardiac catheterization laboratory procedural setting, providers were 2.22 times more likely to prescribe an alternative antiplatelet (p = 0.024). Clopidogrel-naïve patients were 9.75 times more likely to receive a genotype-guided antiplatelet order following alert implementation (p < 0.05).

Conclusion

Providers were responsive to a novel alert within the cardiac catheterization laboratory procedural setting. Genotype-guided antiplatelet prescribing significantly increased following the alert implementation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.70
自引率
0.00%
发文量
0
期刊最新文献
Issue Information A tale of two bills: Lessons learned in expanding pharmacist-led HIV pre-exposure and post-exposure prophylaxis Serving as a professional association board member: Benefits to leaders and their employers Unique model for pharmacist cross-coverage in the ambulatory care setting Issue Information
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1